치료용 백신 시장 분석 및 예측(-2035년) : 유형, 제품 유형, 기술, 용도, 최종 사용자, 컴포넌트, 프로세스, 도입 형태, 솔루션

Therapeutic Vaccines Market is anticipated to expand from $63.8 billion in 2024 to $176.8 billion by 2034, growing at a CAGR of approximately 10.7%. The Therapeutic Vaccines Market encompasses vaccines designed to treat existing diseases by stimulating the immune system to enhance its response. Unlike preventive vaccines, these target chronic infections, cancer, and autoimmune disorders. Advances in biotechnology and increasing prevalence of chronic diseases propel market growth. Key developments include personalized vaccines and novel delivery systems, addressing unmet medical needs and offering promising therapeutic prospects.

The Therapeutic Vaccines Market is experiencing robust growth, propelled by advances in immunotherapy and increasing prevalence of chronic diseases. The cancer vaccines segment leads in performance, driven by innovative treatments targeting tumor antigens. Prophylactic vaccines, particularly for HPV and hepatitis, are gaining momentum due to heightened awareness and prevention strategies. Infectious disease vaccines follow closely, with a focus on novel approaches for HIV and tuberculosis. Personalized vaccines are emerging as a promising area, offering tailored solutions based on individual genetic profiles. Adjuvant technologies are enhancing vaccine efficacy, contributing to market expansion. The rise of mRNA-based vaccines, exemplified by recent successes, underscores the potential for rapid development and deployment. The autoimmune disease vaccines sub-segment is also witnessing growth, as research into diseases like rheumatoid arthritis progresses. Strategic partnerships and collaborations among pharmaceutical companies are fostering innovation and accelerating clinical trials. Regulatory advancements and supportive policies further bolster market dynamics, paving the way for future opportunities.

Market Snapshot:

Therapeutic vaccines are experiencing a dynamic market landscape, characterized by evolving market share, competitive pricing strategies, and a surge in new product launches. The market's growth is propelled by increasing demand for personalized medicine and breakthrough innovations in vaccine technology. Key industry players are strategically introducing advanced therapeutic vaccines to cater to diverse medical needs, enhancing their market presence. Competition in the therapeutic vaccines market is intense, with major companies vying for dominance through innovation and strategic alliances. Regulatory influences play a vital role, as stringent approval processes and compliance standards impact market entry and expansion. North America and Europe are at the forefront, driven by robust healthcare infrastructure and supportive regulatory frameworks. The Asia-Pacific region is emerging as a lucrative market, fueled by rising healthcare investments and increasing awareness. As the industry evolves, opportunities abound for stakeholders who can navigate regulatory landscapes and leverage technological advancements.

Geographical Overview:

The therapeutic vaccines market is witnessing robust growth across various regions, each presenting unique opportunities. North America leads the charge, driven by substantial investments in biotechnology and a strong focus on research and development. The region's well-established healthcare infrastructure and supportive regulatory environment further bolster market expansion. Europe follows closely, with significant advancements in immunotherapy and a growing emphasis on personalized medicine. The region's commitment to innovation and collaboration among key stakeholders enhances its market position. In the Asia Pacific, the market is expanding rapidly, propelled by increasing healthcare expenditure and rising awareness of therapeutic vaccines. Countries like China and India are emerging as key players, with government initiatives supporting biotechnology advancements. Latin America and the Middle East & Africa are burgeoning markets with untapped potential. In Latin America, improved healthcare access and rising demand for advanced treatments drive growth. Meanwhile, the Middle East & Africa are recognizing the benefits of therapeutic vaccines in addressing regional health challenges.

Key Trends and Drivers:

The therapeutic vaccines market is experiencing robust growth, driven by advancements in biotechnology and personalized medicine. Key trends include the development of vaccines targeting chronic diseases such as cancer and autoimmune disorders. These innovations are shifting the focus from traditional prophylactic vaccines to therapeutic applications, offering new avenues for treatment. The integration of cutting-edge technologies like mRNA and viral vector platforms is accelerating the development of more effective vaccines. The rising prevalence of chronic diseases and the growing demand for targeted therapies are significant drivers for this market. Pharmaceutical companies are increasingly investing in research and development to create vaccines that offer personalized treatment options. This trend is supported by increasing regulatory approvals and collaborations between biotech firms and academic institutions. Opportunities abound in emerging markets where healthcare infrastructure is improving, and there is a growing awareness of therapeutic vaccines. Companies that can navigate regulatory landscapes and demonstrate clinical efficacy are well-positioned for success. Additionally, advancements in immunotherapy and the increasing acceptance of combination therapies are expected to further propel market growth. As the focus on personalized healthcare intensifies, the therapeutic vaccines market is poised for substantial expansion.

Restraints and Challenges:

The therapeutic vaccines market is confronted with several notable restraints and challenges. A primary challenge is the high cost of vaccine development, which necessitates substantial investment in research and clinical trials. This financial burden can deter smaller companies and limit innovation. Regulatory hurdles also present significant obstacles; navigating complex approval processes can delay market entry and increase costs. Additionally, the market faces issues with public perception and vaccine hesitancy, which can impede acceptance and uptake. The logistical challenges of distribution, especially in low-resource settings, further complicate market expansion. Ensuring cold chain integrity and reaching remote areas are persistent difficulties. Lastly, the variability in disease prevalence across regions necessitates tailored vaccine solutions, complicating standardization and scalability. These factors collectively pose significant challenges to the growth and accessibility of therapeutic vaccines.

Key Players:

Inovio Pharmaceuticals, Bavarian Nordic, Hookipa Pharma, GlobeImmune, ImmunoVaccine Technologies, Valneva, OncoTherapy Science, Vaxil BioTherapeutics, CEL-SCI Corporation, Transgene, Agenus, Scancell Holdings, Oncolytics Biotech, Genocea Biosciences, Heat Biologics, BioNTech, Altimmune, VBI Vaccines, Imugene, Vaccibody

Research Scope:

• Estimates and forecasts the overall market size across type, application, and region.
• Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
• Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
• Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
• Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
• Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
• Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

• 1.1 Market Size and Forecast
• 1.2 Market Overview
• 1.3 Market Snapshot
• 1.4 Regional Snapshot
• 1.5 Strategic Recommendations
• 1.6 Analyst Notes

2 Market Highlights

• 2.1 Key Market Highlights by Type
• 2.2 Key Market Highlights by Product
• 2.3 Key Market Highlights by Technology
• 2.4 Key Market Highlights by Application
• 2.5 Key Market Highlights by End User
• 2.6 Key Market Highlights by Component
• 2.7 Key Market Highlights by Process
• 2.8 Key Market Highlights by Deployment
• 2.9 Key Market Highlights by Solutions

3 Market Dynamics

• 3.1 Macroeconomic Analysis
• 3.2 Market Trends
• 3.3 Market Drivers
• 3.4 Market Opportunities
• 3.5 Market Restraints
• 3.6 CAGR Growth Analysis
• 3.7 Impact Analysis
• 3.8 Emerging Markets
• 3.9 Technology Roadmap
• 3.10 Strategic Frameworks
  • 3.10.1 PORTER's 5 Forces Model
  • 3.10.2 ANSOFF Matrix
  • 3.10.3 4P's Model
  • 3.10.4 PESTEL Analysis

4 Segment Analysis

• 4.1 Market Size & Forecast by Type (2020-2035)
  • 4.1.1 Cancer Vaccines
  • 4.1.2 Infectious Disease Vaccines
  • 4.1.3 Autoimmune Disease Vaccines
  • 4.1.4 Neurological Disorder Vaccines
• 4.2 Market Size & Forecast by Product (2020-2035)
  • 4.2.1 Prophylactic Vaccines
  • 4.2.2 Therapeutic Vaccines
• 4.3 Market Size & Forecast by Technology (2020-2035)
  • 4.3.1 Recombinant Technology
  • 4.3.2 Conjugate Vaccines
  • 4.3.3 Live Attenuated Vaccines
  • 4.3.4 Inactivated Vaccines
  • 4.3.5 Synthetic Vaccines
• 4.4 Market Size & Forecast by Application (2020-2035)
  • 4.4.1 Oncology
  • 4.4.2 Infectious Diseases
  • 4.4.3 Autoimmune Disorders
  • 4.4.4 Neurological Disorders
• 4.5 Market Size & Forecast by End User (2020-2035)
  • 4.5.1 Hospitals
  • 4.5.2 Clinics
  • 4.5.3 Research Institutes
  • 4.5.4 Pharmaceutical Companies
• 4.6 Market Size & Forecast by Component (2020-2035)
  • 4.6.1 Antigens
  • 4.6.2 Adjuvants
• 4.7 Market Size & Forecast by Process (2020-2035)
  • 4.7.1 Preclinical Testing
  • 4.7.2 Clinical Trials
  • 4.7.3 Manufacturing
• 4.8 Market Size & Forecast by Deployment (2020-2035)
  • 4.8.1 On-premise
  • 4.8.2 Cloud-based
• 4.9 Market Size & Forecast by Solutions (2020-2035)
  • 4.9.1 Vaccine Development
  • 4.9.2 Vaccine Manufacturing
  • 4.9.3 Vaccine Distribution

5 Regional Analysis

• 5.1 Global Market Overview
• 5.2 North America Market Size (2020-2035)
  • 5.2.1 United States
    • 5.2.1.1 Type
    • 5.2.1.2 Product
    • 5.2.1.3 Technology
    • 5.2.1.4 Application
    • 5.2.1.5 End User
    • 5.2.1.6 Component
    • 5.2.1.7 Process
    • 5.2.1.8 Deployment
    • 5.2.1.9 Solutions
  • 5.2.2 Canada
    • 5.2.2.1 Type
    • 5.2.2.2 Product
    • 5.2.2.3 Technology
    • 5.2.2.4 Application
    • 5.2.2.5 End User
    • 5.2.2.6 Component
    • 5.2.2.7 Process
    • 5.2.2.8 Deployment
    • 5.2.2.9 Solutions
  • 5.2.3 Mexico
    • 5.2.3.1 Type
    • 5.2.3.2 Product
    • 5.2.3.3 Technology
    • 5.2.3.4 Application
    • 5.2.3.5 End User
    • 5.2.3.6 Component
    • 5.2.3.7 Process
    • 5.2.3.8 Deployment
    • 5.2.3.9 Solutions
• 5.3 Latin America Market Size (2020-2035)
  • 5.3.1 Brazil
    • 5.3.1.1 Type
    • 5.3.1.2 Product
    • 5.3.1.3 Technology
    • 5.3.1.4 Application
    • 5.3.1.5 End User
    • 5.3.1.6 Component
    • 5.3.1.7 Process
    • 5.3.1.8 Deployment
    • 5.3.1.9 Solutions
  • 5.3.2 Argentina
    • 5.3.2.1 Type
    • 5.3.2.2 Product
    • 5.3.2.3 Technology
    • 5.3.2.4 Application
    • 5.3.2.5 End User
    • 5.3.2.6 Component
    • 5.3.2.7 Process
    • 5.3.2.8 Deployment
    • 5.3.2.9 Solutions
  • 5.3.3 Rest of Latin America
    • 5.3.3.1 Type
    • 5.3.3.2 Product
    • 5.3.3.3 Technology
    • 5.3.3.4 Application
    • 5.3.3.5 End User
    • 5.3.3.6 Component
    • 5.3.3.7 Process
    • 5.3.3.8 Deployment
    • 5.3.3.9 Solutions
• 5.4 Asia-Pacific Market Size (2020-2035)
  • 5.4.1 China
    • 5.4.1.1 Type
    • 5.4.1.2 Product
    • 5.4.1.3 Technology
    • 5.4.1.4 Application
    • 5.4.1.5 End User
    • 5.4.1.6 Component
    • 5.4.1.7 Process
    • 5.4.1.8 Deployment
    • 5.4.1.9 Solutions
  • 5.4.2 India
    • 5.4.2.1 Type
    • 5.4.2.2 Product
    • 5.4.2.3 Technology
    • 5.4.2.4 Application
    • 5.4.2.5 End User
    • 5.4.2.6 Component
    • 5.4.2.7 Process
    • 5.4.2.8 Deployment
    • 5.4.2.9 Solutions
  • 5.4.3 South Korea
    • 5.4.3.1 Type
    • 5.4.3.2 Product
    • 5.4.3.3 Technology
    • 5.4.3.4 Application
    • 5.4.3.5 End User
    • 5.4.3.6 Component
    • 5.4.3.7 Process
    • 5.4.3.8 Deployment
    • 5.4.3.9 Solutions
  • 5.4.4 Japan
    • 5.4.4.1 Type
    • 5.4.4.2 Product
    • 5.4.4.3 Technology
    • 5.4.4.4 Application
    • 5.4.4.5 End User
    • 5.4.4.6 Component
    • 5.4.4.7 Process
    • 5.4.4.8 Deployment
    • 5.4.4.9 Solutions
  • 5.4.5 Australia
    • 5.4.5.1 Type
    • 5.4.5.2 Product
    • 5.4.5.3 Technology
    • 5.4.5.4 Application
    • 5.4.5.5 End User
    • 5.4.5.6 Component
    • 5.4.5.7 Process
    • 5.4.5.8 Deployment
    • 5.4.5.9 Solutions
  • 5.4.6 Taiwan
    • 5.4.6.1 Type
    • 5.4.6.2 Product
    • 5.4.6.3 Technology
    • 5.4.6.4 Application
    • 5.4.6.5 End User
    • 5.4.6.6 Component
    • 5.4.6.7 Process
    • 5.4.6.8 Deployment
    • 5.4.6.9 Solutions
  • 5.4.7 Rest of APAC
    • 5.4.7.1 Type
    • 5.4.7.2 Product
    • 5.4.7.3 Technology
    • 5.4.7.4 Application
    • 5.4.7.5 End User
    • 5.4.7.6 Component
    • 5.4.7.7 Process
    • 5.4.7.8 Deployment
    • 5.4.7.9 Solutions
• 5.5 Europe Market Size (2020-2035)
  • 5.5.1 Germany
    • 5.5.1.1 Type
    • 5.5.1.2 Product
    • 5.5.1.3 Technology
    • 5.5.1.4 Application
    • 5.5.1.5 End User
    • 5.5.1.6 Component
    • 5.5.1.7 Process
    • 5.5.1.8 Deployment
    • 5.5.1.9 Solutions
  • 5.5.2 France
    • 5.5.2.1 Type
    • 5.5.2.2 Product
    • 5.5.2.3 Technology
    • 5.5.2.4 Application
    • 5.5.2.5 End User
    • 5.5.2.6 Component
    • 5.5.2.7 Process
    • 5.5.2.8 Deployment
    • 5.5.2.9 Solutions
  • 5.5.3 United Kingdom
    • 5.5.3.1 Type
    • 5.5.3.2 Product
    • 5.5.3.3 Technology
    • 5.5.3.4 Application
    • 5.5.3.5 End User
    • 5.5.3.6 Component
    • 5.5.3.7 Process
    • 5.5.3.8 Deployment
    • 5.5.3.9 Solutions
  • 5.5.4 Spain
    • 5.5.4.1 Type
    • 5.5.4.2 Product
    • 5.5.4.3 Technology
    • 5.5.4.4 Application
    • 5.5.4.5 End User
    • 5.5.4.6 Component
    • 5.5.4.7 Process
    • 5.5.4.8 Deployment
    • 5.5.4.9 Solutions
  • 5.5.5 Italy
    • 5.5.5.1 Type
    • 5.5.5.2 Product
    • 5.5.5.3 Technology
    • 5.5.5.4 Application
    • 5.5.5.5 End User
    • 5.5.5.6 Component
    • 5.5.5.7 Process
    • 5.5.5.8 Deployment
    • 5.5.5.9 Solutions
  • 5.5.6 Rest of Europe
    • 5.5.6.1 Type
    • 5.5.6.2 Product
    • 5.5.6.3 Technology
    • 5.5.6.4 Application
    • 5.5.6.5 End User
    • 5.5.6.6 Component
    • 5.5.6.7 Process
    • 5.5.6.8 Deployment
    • 5.5.6.9 Solutions
• 5.6 Middle East & Africa Market Size (2020-2035)
  • 5.6.1 Saudi Arabia
    • 5.6.1.1 Type
    • 5.6.1.2 Product
    • 5.6.1.3 Technology
    • 5.6.1.4 Application
    • 5.6.1.5 End User
    • 5.6.1.6 Component
    • 5.6.1.7 Process
    • 5.6.1.8 Deployment
    • 5.6.1.9 Solutions
  • 5.6.2 United Arab Emirates
    • 5.6.2.1 Type
    • 5.6.2.2 Product
    • 5.6.2.3 Technology
    • 5.6.2.4 Application
    • 5.6.2.5 End User
    • 5.6.2.6 Component
    • 5.6.2.7 Process
    • 5.6.2.8 Deployment
    • 5.6.2.9 Solutions
  • 5.6.3 South Africa
    • 5.6.3.1 Type
    • 5.6.3.2 Product
    • 5.6.3.3 Technology
    • 5.6.3.4 Application
    • 5.6.3.5 End User
    • 5.6.3.6 Component
    • 5.6.3.7 Process
    • 5.6.3.8 Deployment
    • 5.6.3.9 Solutions
  • 5.6.4 Sub-Saharan Africa
    • 5.6.4.1 Type
    • 5.6.4.2 Product
    • 5.6.4.3 Technology
    • 5.6.4.4 Application
    • 5.6.4.5 End User
    • 5.6.4.6 Component
    • 5.6.4.7 Process
    • 5.6.4.8 Deployment
    • 5.6.4.9 Solutions
  • 5.6.5 Rest of MEA
    • 5.6.5.1 Type
    • 5.6.5.2 Product
    • 5.6.5.3 Technology
    • 5.6.5.4 Application
    • 5.6.5.5 End User
    • 5.6.5.6 Component
    • 5.6.5.7 Process
    • 5.6.5.8 Deployment
    • 5.6.5.9 Solutions

6 Market Strategy

• 6.1 Demand-Supply Gap Analysis
• 6.2 Trade & Logistics Constraints
• 6.3 Price-Cost-Margin Trends
• 6.4 Market Penetration
• 6.5 Consumer Analysis
• 6.6 Regulatory Snapshot

7 Competitive Intelligence

• 7.1 Market Positioning
• 7.2 Market Share
• 7.3 Competition Benchmarking
• 7.4 Top Company Strategies

8 Company Profiles

• 8.1 Inovio Pharmaceuticals
  • 8.1.1 Overview
  • 8.1.2 Product Summary
  • 8.1.3 Financial Performance
  • 8.1.4 SWOT Analysis
• 8.2 Bavarian Nordic
  • 8.2.1 Overview
  • 8.2.2 Product Summary
  • 8.2.3 Financial Performance
  • 8.2.4 SWOT Analysis
• 8.3 Hookipa Pharma
  • 8.3.1 Overview
  • 8.3.2 Product Summary
  • 8.3.3 Financial Performance
  • 8.3.4 SWOT Analysis
• 8.4 GlobeImmune
  • 8.4.1 Overview
  • 8.4.2 Product Summary
  • 8.4.3 Financial Performance
  • 8.4.4 SWOT Analysis
• 8.5 ImmunoVaccine Technologies
  • 8.5.1 Overview
  • 8.5.2 Product Summary
  • 8.5.3 Financial Performance
  • 8.5.4 SWOT Analysis
• 8.6 Valneva
  • 8.6.1 Overview
  • 8.6.2 Product Summary
  • 8.6.3 Financial Performance
  • 8.6.4 SWOT Analysis
• 8.7 OncoTherapy Science
  • 8.7.1 Overview
  • 8.7.2 Product Summary
  • 8.7.3 Financial Performance
  • 8.7.4 SWOT Analysis
• 8.8 Vaxil BioTherapeutics
  • 8.8.1 Overview
  • 8.8.2 Product Summary
  • 8.8.3 Financial Performance
  • 8.8.4 SWOT Analysis
• 8.9 CEL-SCI Corporation
  • 8.9.1 Overview
  • 8.9.2 Product Summary
  • 8.9.3 Financial Performance
  • 8.9.4 SWOT Analysis
• 8.10 Transgene
  • 8.10.1 Overview
  • 8.10.2 Product Summary
  • 8.10.3 Financial Performance
  • 8.10.4 SWOT Analysis
• 8.11 Agenus
  • 8.11.1 Overview
  • 8.11.2 Product Summary
  • 8.11.3 Financial Performance
  • 8.11.4 SWOT Analysis
• 8.12 Scancell Holdings
  • 8.12.1 Overview
  • 8.12.2 Product Summary
  • 8.12.3 Financial Performance
  • 8.12.4 SWOT Analysis
• 8.13 Oncolytics Biotech
  • 8.13.1 Overview
  • 8.13.2 Product Summary
  • 8.13.3 Financial Performance
  • 8.13.4 SWOT Analysis
• 8.14 Genocea Biosciences
  • 8.14.1 Overview
  • 8.14.2 Product Summary
  • 8.14.3 Financial Performance
  • 8.14.4 SWOT Analysis
• 8.15 Heat Biologics
  • 8.15.1 Overview
  • 8.15.2 Product Summary
  • 8.15.3 Financial Performance
  • 8.15.4 SWOT Analysis
• 8.16 BioNTech
  • 8.16.1 Overview
  • 8.16.2 Product Summary
  • 8.16.3 Financial Performance
  • 8.16.4 SWOT Analysis
• 8.17 Altimmune
  • 8.17.1 Overview
  • 8.17.2 Product Summary
  • 8.17.3 Financial Performance
  • 8.17.4 SWOT Analysis
• 8.18 VBI Vaccines
  • 8.18.1 Overview
  • 8.18.2 Product Summary
  • 8.18.3 Financial Performance
  • 8.18.4 SWOT Analysis
• 8.19 Imugene
  • 8.19.1 Overview
  • 8.19.2 Product Summary
  • 8.19.3 Financial Performance
  • 8.19.4 SWOT Analysis
• 8.20 Vaccibody
  • 8.20.1 Overview
  • 8.20.2 Product Summary
  • 8.20.3 Financial Performance
  • 8.20.4 SWOT Analysis

9 About Us

• 9.1 About Us
• 9.2 Research Methodology
• 9.3 Research Workflow
• 9.4 Consulting Services
• 9.5 Our Clients
• 9.6 Client Testimonials
• 9.7 Contact Us